


Please type a plus sign (+) inside this box →

+



PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/747,691	
		Filing Date	December 30, 2003	
		First Named Inventor	STEINER, Mitchell S.	
		Group Art Unit		
		Examiner Name		
Sheet		of	Attorney Docket Number	P-4595-US2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/KW/	H	O'Brien Frank M. et al "Insulin-like Growth Fact I and Prostate Cancer", 2001 Elsevier Science Inc, Urology 58:1-7, 2001	<input type="checkbox"/>
/KW/	I	Horwitz Eric M. et al "Subset Analysis of RTOG 85031 and 86-10 Indicates An Advantage For Long-Term vs. Short-Terms Adjuvant Hormones For Patients With Locally Advanced Nonmetastatic Prostate Cancer Treated with Radiation Therapy", Int. J Radiation Oncology Biol. Phys. Vol. 49, No. 4 pp. 947-956, 2001, Elsevier Science Inc.	<input type="checkbox"/>
/KW/	J	Messing Edward M. et al "Immediate Hormonal Therapy Compared With Observation After Radical Prostatectomy and Pelvic Lymphadenectomy in Men With Node-Positive Prostate Cancer" The New England Journal of Medicine, 1999 Vol. 341, No. 24	<input type="checkbox"/>
/KW/	K	Newling Don W.W. "Early Versus Late Androgen Deprivation Therapy in Metastatic Disease", Elsevier Science Inc, Urology 58 (supplement 2A), August 2001	<input type="checkbox"/>
/KW/	L	Jordan Craig V. "Antiestrogenic Action of Raloxifene and Tamoxifen: Today and Tomorrow" Journal of National Cancer Institute, Vol. 90, No. 13, July 1, 1998	<input type="checkbox"/>
/KW/	M	Buelke-Sam J. et al. "The Selective Estrogen Receptor Modulator, Raloxifene: An Overview Of NonClinical Pharmacology And Reproductive And Developmental Testing", Reprod Toxicol 1998 May-June; 12(3):217-21.	<input type="checkbox"/>
/KW/	N	Steger Reinhard et al. "Potential Side-Effects of Endocrine Treatment of Long Duration in Prostate Cancer" The Prostate Supplement 10:38-42, 2000	<input type="checkbox"/>
/KW/	O	Goodson Max J. "Dental Applications" Vol. II, Chapter 6,	<input type="checkbox"/>

Examiner Signature	/Kevin Weddington/ (03/30/2007)	Date Considered	
--------------------	---------------------------------	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 20 hours to complete Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete If Known

Application Number	10/747,691
Filing Date	December 30, 2003
First Named Inventor	STEINER, Mitchell S.
Art Unit	1615
Examiner Name	Not yet known
Attorney Docket Number	P-4595-US2

Sheet	1	of	2
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

/Kevin Weddington/ (03/30/2007)

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete If Known	
				Application Number	10/747,691
				Filing Date	December 30, 2003
				First Named Inventor	STEINER, Mitchell S.
				Art Unit	1615
				Examiner Name	Not yet known
Sheet	2	of	2	Attorney Docket Number	P-4595-US2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/KW/	E	Staiman, et al (1997) "Tamoxifen For Flutamide.Finasteride-Induced Gynecomastia" Urology 50: 6	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>

Examiner Signature	/Kevin Weddington/ (03/30/2007)	Date Considered	
-----------------------	---------------------------------	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered
Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2